Cullinan Therapeutics (CGEM) News
NASDAQ: CGEMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
8.89-0.18 (-1.98%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CGEM news summary
We found 12 recent headlines mentioning Cullinan Therapeutics (CGEM): 0 in the past week and 12 in the past 30 days, most often from GlobeNewswire, Nasdaq, Seeking Alpha. For price context, CGEM is down 1.98% at $8.89. The most recent story, "Cullinan Partner Taiho Completes FDA Filing For Zipalertinib Combo In First-Line Lung Cancer", was published by Nasdaq on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Cullinan Therapeutics headlines
- Cullinan Partner Taiho Completes FDA Filing For Zipalertinib Combo In First-Line Lung Cancer(RTTNews) - Cullinan Therapeutics, Inc. (CGEM) said its partner Taiho Oncology completed a New Drug Application (NDA) submission to the U.S. FDA for zipalertinib with platinum-based chemotherapy.NasdaqCGEM, WSO.B
- New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung CancerSubmission is based on Phase 3 REZILIENT3 data in first-line EGFR ex20ins NSCLC Submission is based on Phase 3 REZILIENT3 data in first-line EGFR ex20ins NSCLCGlobeNewswire
- Cullinan Therapeutics reports Q3 resultsSeeking Alpha
- Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsCLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA, and Sjögren’s disease will be shared in DecemberGlobeNewswire
- Cullinan Therapeutics Announces Velinotamig Clinical Data Presented at ACR Convergence 2026On November 8, 2026, Cullinan Therapeutics, Inc. announced clinical data from the ongoing Phase 1b/2a clinical trial in velinotamig in patients with active, refractory, moderate-to-severe systemic…Nasdaq
- Cullinan Therapeutics to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class,…GlobeNewswire
- Cullinan Reports Phase 1b/2a Study Data For Velinotamig In SLE Patients; Stock Up(RTTNews) - Cullinan Therapeutics, Inc. (CGEM), a clinical-stage biopharmaceutical company, announced clinical data from the ongoing Genrix Bio Phase 1b/2a study of velinotamig (GR1803) in patients…NasdaqCGEM, BF.A
- Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026Clinically meaningful improvement in disease activity among 8 of 9 evaluable patients, including rapid and marked reductions in proteinuria with complete renal responsesGlobeNewswire
- Cullinan Therapeutics Reports Phase 1 Trial Data for CLN-049 with 19% and 21% CRc Rates in AML and MDS PatientsCullinan Therapeutics, Inc. shared updated data from its Phase 1 dose escalation clinical trial for CLN-049 in patients with relapsed or refractory AML or MDS. As of the data cutoff, 87 patients (76…Nasdaq
- Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual MeetingCAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class,…GlobeNewswire
- 3 Growth Stocks Under $20 With Hard Catalyst Dates AheadSmall caps led the market into spring and have been handing it back ever since. The Russell 2000 has cooled, defense and drone names sit well off their highs, and the riskier corners of biotech and…NasdaqCGEM, KOPN, GRMN
- Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDAGlobal regulatory clearances in the U.S. and Australia support initiation of a Phase 1b/2a study in relapsing and refractory ITP and wAIHAGlobeNewswire